Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

The oncogenic properties of the HMG-I gene family.

Wood LJ, Maher JF, Bunton TE, Resar LM.

Cancer Res. 2000 Aug 1;60(15):4256-61.

2.

Tumor promoter induces high mobility group HMG-Y protein expression in transformation-sensitive but not -resistant cells.

Cmarik JL, Li Y, Ogram SA, Min H, Reeves R, Colburn NH.

Oncogene. 1998 Jul 2;16(26):3387-96.

3.

HMG-I/Y, a new c-Myc target gene and potential oncogene.

Wood LJ, Mukherjee M, Dolde CE, Xu Y, Maher JF, Bunton TE, Williams JB, Resar LM.

Mol Cell Biol. 2000 Aug;20(15):5490-502.

4.

Structure and function of the HMGI(Y) family of architectural transcription factors.

Reeves R.

Environ Health Perspect. 2000 Oct;108 Suppl 5:803-9. Review.

PMID:
11035986
6.
7.

HMG-I/Y in human breast cancer cell lines.

Dolde CE, Mukherjee M, Cho C, Resar LM.

Breast Cancer Res Treat. 2002 Feb;71(3):181-91.

PMID:
12002338
8.

The architectural transcription factor high mobility group I(Y) participates in photoreceptor-specific gene expression.

Chau KY, Munshi N, Keane-Myers A, Cheung-Chau KW, Tai AK, Manfioletti G, Dorey CK, Thanos D, Zack DJ, Ono SJ.

J Neurosci. 2000 Oct 1;20(19):7317-24.

9.

HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cells.

Hommura F, Katabami M, Leaner VD, Donninger H, Sumter TF, Resar LM, Birrer MJ.

Mol Cancer Res. 2004 May;2(5):305-14.

10.

FR900482 class of anti-tumor drugs cross-links oncoprotein HMG I/Y to DNA in vivo.

Beckerbauer L, Tepe JJ, Cullison J, Reeves R, Williams RM.

Chem Biol. 2000 Oct;7(10):805-12.

11.

Decreased tumorigenicity of c-Myc-transformed fibroblasts expressing active USF2.

Choe C, Chen N, Sawadogo M.

Exp Cell Res. 2005 Jan 1;302(1):1-10.

PMID:
15541720
12.

HMGI-C gene expression is not required for in vivo thyroid cell transformation.

Scala S, Portella G, Vitagliano D, Ledent C, Chiappetta G, Giancotti V, Dumont J, Fusco A.

Carcinogenesis. 2001 Feb;22(2):251-6.

PMID:
11181445
13.

HMGI(Y) and HMGI-C dysregulation: a common occurrence in human tumors.

Tallini G, Dal Cin P.

Adv Anat Pathol. 1999 Sep;6(5):237-46. Review.

PMID:
10472377
14.

Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation.

Chen H, Liu J, Zhao CQ, Diwan BA, Merrick BA, Waalkes MP.

Toxicol Appl Pharmacol. 2001 Sep 15;175(3):260-8.

PMID:
11559025
15.

Down-regulation of high mobility group-I(Y) protein contributes to the inhibition of nitric-oxide synthase 2 by transforming growth factor-beta1.

Pellacani A, Wiesel P, Razavi S, Vasilj V, Feinberg MW, Chin MT, Reeves R, Perrella MA.

J Biol Chem. 2001 Jan 12;276(2):1653-9.

16.

The high mobility group protein, HMGI-C.

Goodwin G.

Int J Biochem Cell Biol. 1998 Jul;30(7):761-6. Review.

PMID:
9722980
17.

Induction of high mobility group I architectural transcription factors in proliferating vascular smooth muscle in vivo and in vitro.

Chin MT, Pellacani A, Hsieh CM, Lin SS, Jain MK, Patel A, Huggins GS, Reeves R, Perrella MA, Lee ME.

J Mol Cell Cardiol. 1999 Dec;31(12):2199-205.

PMID:
10640447
18.
19.

The oncogenic potential of the high mobility group box protein Sox3.

Xia Y, Papalopulu N, Vogt PK, Li J.

Cancer Res. 2000 Nov 15;60(22):6303-6.

20.

Expression of mRNAs encoding mammalian chromosomal proteins HMG-I and HMG-Y during cellular proliferation.

Johnson KR, Disney JE, Wyatt CR, Reeves R.

Exp Cell Res. 1990 Mar;187(1):69-76.

PMID:
2404776

Supplemental Content

Support Center